196 related articles for article (PubMed ID: 33501771)
1. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.
Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R
Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771
[TBL] [Abstract][Full Text] [Related]
2. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS
Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768
[TBL] [Abstract][Full Text] [Related]
3. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Rodeberg DA; Wharam MD; Lyden ER; Stoner JA; Brown K; Wolden SL; Paidas CN; Donaldson SS; Hawkins DS; Spunt SL; Arndt CA
Int J Cancer; 2015 Jul; 137(1):204-11. PubMed ID: 25418440
[TBL] [Abstract][Full Text] [Related]
4. Treatment and outcome of the patients with rhabdomyosarcoma of the biliary tree: Experience of the Cooperative Weichteilsarkom Studiengruppe (CWS).
Urla C; Warmann SW; Sparber-Sauer M; Schuck A; Leuschner I; Klingebiel T; Blumenstock G; Seitz G; Koscielniak E; Fuchs J
BMC Cancer; 2019 Oct; 19(1):945. PubMed ID: 31610788
[TBL] [Abstract][Full Text] [Related]
5. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
7. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.
Minard-Colin V; Walterhouse D; Bisogno G; Martelli H; Anderson J; Rodeberg DA; Ferrari A; Jenney M; Wolden S; De Salvo G; Arndt C; Merks JHM; Gallego S; Schwob D; Haie-Meder C; Bergeron C; Stevens MCG; Oberlin O; Hawkins D;
Pediatr Blood Cancer; 2018 Sep; 65(9):e27096. PubMed ID: 29781567
[TBL] [Abstract][Full Text] [Related]
8. Local therapy for rhabdomyosarcoma of the hands and feet: is amputation necessary? A report from the Children's Oncology Group.
La TH; Wolden SL; Su Z; Linardic C; Randall RL; Hawkins DS; Donaldson SS
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):206-12. PubMed ID: 20646853
[TBL] [Abstract][Full Text] [Related]
9. Significance of delayed primary excision in localized nonmetastatic adult head and neck rhabdomyosarcoma.
Kobayashi K; Matsumoto F; Kodaira M; Mori T; Murakami N; Yoshida A; Maki D; Teshima M; Fukasawa M; Itami J; Asai M; Yoshimoto S
Cancer Med; 2016 Oct; 5(10):2708-2714. PubMed ID: 27565892
[TBL] [Abstract][Full Text] [Related]
10. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Li M; Wolden SL; Casey DL; Routh JC; Granberg CF; Binite O; Rudzinski ER; Hawkins DS; Venkatramani R; Rodeberg DA
Cancer; 2021 Jan; 127(2):275-283. PubMed ID: 33079399
[TBL] [Abstract][Full Text] [Related]
11. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
12. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
13. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
[TBL] [Abstract][Full Text] [Related]
14. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
15. Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.
Aye JM; Chi YY; Tian J; Rudzinski ER; Binitie OT; Dasgupta R; Wolden SL; Hawkins DS; Gupta AA
Pediatr Blood Cancer; 2020 May; 67(5):e28243. PubMed ID: 32124549
[TBL] [Abstract][Full Text] [Related]
16. The impact of surgical excision in chest wall rhabdomyosarcoma: a report from the Children's Oncology Group.
Hayes-Jordan A; Stoner JA; Anderson JR; Rodeberg D; Weiner G; Meyer WH; Hawkins DS; Arndt CA; Paidas C;
J Pediatr Surg; 2008 May; 43(5):831-6. PubMed ID: 18485948
[TBL] [Abstract][Full Text] [Related]
17. Aggressive surgery is unwarranted for biliary tract rhabdomyosarcoma.
Spunt SL; Lobe TE; Pappo AS; Parham DM; Wharam MD; Arndt C; Anderson JR; Crist WM; Paidas C; Wiener E; Andrassy RJ; Schwartz CL
J Pediatr Surg; 2000 Feb; 35(2):309-16. PubMed ID: 10693686
[TBL] [Abstract][Full Text] [Related]
18. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG.
Donaldson SS; Meza J; Breneman JC; Crist WM; Laurie F; Qualman SJ; Wharam M;
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):718-28. PubMed ID: 11597814
[TBL] [Abstract][Full Text] [Related]
19. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
20. Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children's Oncology Group.
Russell H; Swint JM; Lal L; Meza J; Walterhouse D; Hawkins DS; Okcu MF
Pediatr Blood Cancer; 2014 Jun; 61(6):970-6. PubMed ID: 24453105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
